The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility
Abstract
Executive Summary: As the leading organization representing cancer specialists involved in patient care and clinical research, the American Society of Clinical Oncology (ASCO) reaffirms its commitment to integrating cancer risk assessment and management, including molecular analysis of cancer predisposition genes, into the practice of oncology and preventive medicine. The primary goal of this effort is to foster expanded access to, and continued advances in, medical care provided to patients and families affected by hereditary cancer syndromes. The 1996 ASCO Statement on Genetic Testing for Cancer Susceptibility set forth specific recommendations relating to clinical practice, research needs, educational opportunities, requirement for informed consent, indications for genetic testing, regulation of laboratories, and protection from discrimination, as well as access to and reimbursement for cancer genetics services. In updating this Statement, ASCO endorses the following principles: Indications for Genetic Testing:ASCO recommends that genetic testing be offered when 1) the individual has personal or family history features suggestive of a genetic cancer susceptibility condition, 2) the test can be adequately interpreted, and 3) the results will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer. ASCO recommends that genetic testing only be done in the setting of pre- and post-test counseling, which should include discussion of possible risks and benefits of cancer early detection and prevention modalities. Special Issues in Testing Children for Cancer Susceptibility:ASCO recommends that the decision to offer testing to potentially affected children should take into account the availability of evidence-based risk-reduction strategies and the probability of developing a malignancy during childhood. Where risk-reduction strategies are available or cancer predominantly develops in childhood, ASCO believes that the scope of parental authority encompasses the right to decide for or against testing. In the absence of increased risk of a childhood malignancy, ASCO recommends delaying genetic testing until an individual is of sufficient age to make an informed decision regarding such tests. As in other areas of pediatric care, the clinical cancer genetics professional should be an advocate for the best interests of the child. Counseling About Medical Management After Testing:ASCO recommends that oncologists include in pre- and post-test counseling the discussion of possible risks and benefits of cancer early-detection and prevention modalities, some of which have presumed but unproven efficacy for individuals at increased hereditary risk of cancer. Regulation of Genetic Testing:ASCO recommends strengthening regulatory oversight of laboratories that provide clinical cancer predisposition tests. These quality assurance mechanisms should include oversight of the reagents used in genetic testing, interlaboratory comparisons of reference samples, standardization of laboratory genetic test reports, and proficiency testing. Protection From Insurance and Employment Discrimination:ASCO supports establishing a federal law to prohibit discrimination by health insurance providers and employers on the basis of an individual’s inherited susceptibility to cancer. Protections against genetic discrimination should apply to those with group coverage, those with individual health insurance policies, and the uninsured. Coverage of Services:ASCO supports efforts to ensure that all individuals at significantly increased risk of hereditary cancer have access to appropriate genetic counseling, testing, screening, surveillance, and all related medical and surgical interventions, which should be covered without penalty by public and private third-party payers. Confidentiality and Communication of Familial Risk:ASCO recommends that providers make concerted efforts to protect the confidentiality of genetic information. However, they should remind patients of the importance of communicating test results to family members, as part of pretest counseling and informed consent discussions. ASCO believes that the cancer care provider’s obligations (if any) to at-risk relatives are best fulfilled by communication of familial risk to the person undergoing testing, emphasizing the importance of sharing this information with family members so that they may also benefit. Educational Opportunities in Genetics:ASCO is committed to continuing to provide educational opportunities for physicians and other health care providers regarding the methods of cancer risk assessment, the clinical characteristics of hereditary cancer susceptibility syndromes, and the range of issues related to genetic testing, including pre- and post-test genetic counseling, and risk management, so that health professionals may responsibly integrate the care of persons at increased genetic risk of cancer into the practice of clinical and preventive oncology. Special Issues Relating to Genetic Research on Human Tissues:ASCO recommends that all researchers proposing to use or store human biologic specimens for genetic studies should consult either the responsible institutional review board (IRB) or a comparable body specifically constituted to assess human tissue research, to determine the requirements for protection specific to the study under consideration. This consultation should take place before the project is initiated. The determination of the need for informed consent or authorization in such studies should depend on whether the research involves tests for genetic markers of known clinical significance and whether research data will be linked to protected health information, as well as other considerations specific to the study proposed. Special attention should also be paid to 1) whether future research findings will be disclosed to the research participants, 2) whether future contact of participants is planned, 3) whether and how protected health information about the tissue donors will be stored, and what will happen to study specimens after the trial ends. In addition, ASCO affirms the right of people contributing tissue to a databank to rescind their permission, in accordance with federal privacy regulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Informed Consent, Parental Permission, and Assent in Pediatric Practice
Committee on Bioethics (1995) · Pediatrics · doi:10.1542/peds.95.2.314 · Cited by 956
Informed Consent, Parental Permission, and Assent in Pediatric Practice
Bartholome, W. G. (1995) · Pediatrics · doi:10.1542/peds.96.5.981 · Cited by 653
The Use and Interpretation of Commercial APC Gene Testing for Familial Adenomatous Polyposis
Giardiello, F. M., Brensinger, J. D., Petersen, G. M., Luce, M. C., Hylind, L. M., Bacon, J. A., Booker, S. V., Parker, R. D., & Hamilton, S. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703203361202 · Cited by 498
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1730 · Cited by 484
Thibodeau, S. N., French, A. J., Roche, P. C., Cunningham, J. M., Tester, D. J., Lindor, N. M., Möslein, G., Baker, S. M., Liskay, R. M., Burgart, L. J., et al. (1996) · PubMed · Cited by 466
Ethical Issues With Genetic Testing in Pediatrics
Committee on Bioethics (2001) · Pediatrics · doi:10.1542/peds.107.6.1451 · Cited by 364
Informed Consent for Genetic Research on Stored Tissue Samples
Clayton, E. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220052033 · Cited by 283
Genetic testing for children and adolescents. Who decides?
Wertz, D. C. (1994) · JAMA · doi:10.1001/jama.272.11.875 · Cited by 279
Informed Consent for Population-Based Research Involving Genetics
Beskow, L. M. (2001) · JAMA · doi:10.1001/jama.286.18.2315 · Cited by 272
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Familial adenomatous polyposis
Galiatsatos, P., & Foulkes, W. D. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00375.x · Cited by 757
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Dimaras, H., Kimani, K., Dimba, E. A., Gronsdahl, P., White, A., Chan, H. S., & Gallie, B. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61137-9 · Cited by 669
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Parsons, D. W., Roy, A., Yang, Y., Wang, T., Scollon, S., Bergstrom, K., Kerstein, R. A., Gutierrez, S., Petersen, A. K., Bavle, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5699 · Cited by 491
Breast Cancer Screening and Diagnosis
Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., Dempsey, P. J., Farrar, W. B., Fleming, I., Garber, J. E., Harris, R. E., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0070 · Cited by 465
Peutz-Jeghers Syndrome and Management Recommendations
Giardiello, F. M., & Trimbath, J. D. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.11.005 · Cited by 448
Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., Novokmet, A., Finlay, J., & Malkin, D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70119-x · Cited by 423
Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0660 · Cited by 421
Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome
Chen, S., Wang, W., Lee, S., Nafa, K., Lee, J., Romans, K., Watson, P., Gruber, S. B., Euhus, D., Kinzler, K. W., et al. (2006) · JAMA · doi:10.1001/jama.296.12.1479 · Cited by 384
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., Callif‐Daley, F., Grumet, S. C., Hunt, K. S., Nagy, R. S., et al. (2012) · Journal of Genetic Counseling · doi:10.1007/s10897-011-9462-x · Cited by 328
Advances in counselling and surveillance of patients at risk for pancreatic cancer: Table 1
Brand, R. E., Lerch, M. M., Rubinstein, W. S., Neoptolemos, J. P., Whitcomb, D. C., Hruban, R. H., Brentnall, T. A., Lynch, H. T., & Canto, M. I. (2007) · Gut · doi:10.1136/gut.2006.108456 · Cited by 323
Murff, H. J., Spigel, D. R., & Syngal, S. (2004) · JAMA · doi:10.1001/jama.292.12.1480 · Cited by 316
Green, M. J., Peterson, S. K., Baker, M. W., Harper, G. R., Friedman, L. C., Rubinstein, W. S., & Mauger, D. T. (2004) · JAMA · doi:10.1001/jama.292.4.442 · Cited by 290
Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., Manley, S., Culver, J. O., Acton, R., Larsen‐Haidle, J., et al. (2004) · Journal of Genetic Counseling · doi:10.1023/b:jogc.0000018821.48330.77 · Cited by 264
Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Schwartz, M. D., Valdimarsdottir, H. B., Peshkin, B. N., Mandelblatt, J., Nusbaum, R., Huang, A.-T., Chang, Y., Graves, K., Isaacs, C., Wood, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.3226 · Cited by 253
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, I., Somerfield, M. R., Achatz, M. I., Boughey, J. C., Curigliano, G., Friedman, S., Kohlmann, W. K., Kurian, A. W., Laronga, C., Lynce, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02225 · Cited by 216
Dinh, T. A., Rosner, B. I., Atwood, J. C., Boland, C. R., Syngal, S., Vasen, H. F. A., Gruber, S. B., & Burt, R. W. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0262 · Cited by 175
At-Risk Populations for Osteosarcoma: The Syndromes and Beyond
Calvert, G. T., Randall, R. L., Jones, K. B., Cannon-Albright, L., Lessnick, S., & Schiffman, J. D. (2012) · Sarcoma · doi:10.1155/2012/152382 · Cited by 90
Lucas, A. L., Frado, L. E., Hwang, C., Kumar, S., Khanna, L. G., Levinson, E. J., Chabot, J. A., Chung, W. K., & Frucht, H. (2014) · Cancer · doi:10.1002/cncr.28662 · Cited by 68
Vetsch, J., Wakefield, C. E., Warby, M., Tucker, K., Patterson, P., McGill, B. C., Metcalfe, A., Cohn, R. J., & Fardell, J. E. (2018) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2017.0102 · Cited by 26
Metadata
- Venue
- Journal of Clinical Oncology
- Published
- 2003-06-15
- Volume
- 21
- Issue
- 12
- Pages
- 2397-2406
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2181086016
- Cited by
- 751
- References
- 12
- FWCI
- 22.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.